Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

The introduction of CDK4/6 inhibitors in combination with endocrine therapy (ET) represents the most relevant advance in the management of hormone receptor (HR) positive, HER2-negative metastatic breast cancer over the last few years. This meta-analysis of randomized controlled trials (RCTs) is aime...

Full description

Bibliographic Details
Main Authors: Michela Piezzo, Paolo Chiodini, Maria Riemma, Stefania Cocco, Roberta Caputo, Daniela Cianniello, Germira Di Gioia, Vincenzo Di Lauro, Francesca Di Rella, Giuseppina Fusco, Giovanni Iodice, Francesco Nuzzo, Carmen Pacilio, Matilde Pensabene, Michelino De Laurentiis
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
epidemiology
cancer
metastatic breast cancer
hormone therapy
CDK4/6 inhibitors
overall survival
Online Access:https://www.mdpi.com/1422-0067/21/17/6400

Internet

https://www.mdpi.com/1422-0067/21/17/6400

Similar Items